Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
- Klíčová slova
- Acute myeloid leukemia, FLT3 mutation, Fms-like tyrosine kinase 3, anticancer drug discovery, patent review,
- MeSH
- akutní myeloidní leukemie * genetika farmakoterapie patologie MeSH
- chemorezistence MeSH
- individualizovaná medicína metody MeSH
- inhibitory proteinkinas * farmakologie škodlivé účinky aplikace a dávkování MeSH
- lidé MeSH
- mutace MeSH
- patenty jako téma MeSH
- prognóza MeSH
- protinádorové látky * farmakologie škodlivé účinky MeSH
- staurosporin analogy a deriváty MeSH
- tyrosinkinasa 3 podobná fms * genetika antagonisté a inhibitory MeSH
- vyvíjení léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- FLT3 protein, human MeSH Prohlížeč
- inhibitory proteinkinas * MeSH
- midostaurin MeSH Prohlížeč
- protinádorové látky * MeSH
- staurosporin MeSH
- tyrosinkinasa 3 podobná fms * MeSH
INTRODUCTION: Approximately one-third of all AML patients have a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene, which is associated with a poor prognosis in these individuals. The 2017 approval of midostaurin, the first FLT3 inhibitor, spurred extensive development of more potent and selective inhibitors with an improved safety profile. AREAS COVERED: This review analyzes patent inventions for the treatment of AML using FLT3 inhibitors, covering developments from the earliest to the most recent, disclosed in 2024. Our search using the global Espacenet database identified numerous compounds with low nanomolar inhibitory concentrations against FLT3-ITD and FLT3-TKD mutants. These compounds have shown promise in preclinical studies. Co-inhibition strategies and combinatorial therapies to overcome resistance and enhance anti-leukemic efficacy are also discussed. EXPERT OPINION: Recent patents highlight advances in the field of FLT3 inhibitors with a focus on overcoming resistance, improving selectivity and potency. Future strategies may include third-generation inhibitors such as type III allosteric inhibitors, irreversible inhibitors, or PROTACs. Personalized medicine approaches utilizing genetic profiling to tailor therapies are emphasized. Exploration of novel combination regimens with emerging therapies like CAR T-cell therapy, immune checkpoint inhibitors, and small molecules targeting critical AML pathways is ongoing to further enhance anti-leukemic efficacy.
Biomedical Research Centre University Hospital Hradec Kralove Hradec Kralove Czech Republic
Department of Experimental Biology Faculty of Science Palacký University Olomouc Czech Republic
Citace poskytuje Crossref.org
